Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg Daily or 550 mg Twice Daily) for Chemoprophylaxis Against Travelers' Diarrhea (TD) Among Active Duty Deployed U.S. and British Military Personnel

NCT02498301 is registered in ClinicalTrials.gov with Henry M. Jackson Foundation for the Advancement of Military Medicine as lead sponsor.

NCT NCT02498301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02498301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg Daily or 550 mg Twice Daily) for Chemoprophylaxis Against Travelers' Diarrhea (TD) Among Active Duty Deployed U.S. and British Military Personnel
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Phase
Not applicable
Overall status
Completed
Start date
November 10, 2015
Completion date
December 31, 2019
Enrollment
449 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

functional bowel disorders, reactive arthritis, travelers' diarrhea